Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03684733
Other study ID # CCR 4173
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 13, 2017
Est. completion date November 15, 2019

Study information

Verified date March 2020
Source Royal Marsden NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a combination retrospective/prospective observational study with two arms:


Description:

Arm 1 :To establish the accuracy of MRI measurements from clinical MRI sequences

Cohort 1: Participants attending MRI & XRM for a clinical indication with at least one normal breast

Women attend MRI and XRM at the Royal Marsden NHS Foundation Trust for a wide range of clinical indications, including screening, staging and disease monitoring. Investigators will retrospectively analyse MRI and XRM examinations from women with at least one normal breast. This will enable a comparison of clinical and research MRI techniques to measure MRI Breast Density and BPE together with a correlation against PMD. This cohort should cover a wide range of ages and breast densities which will enable a useful comparison of measurement techniques.

Arm 2 To compare breast tissue between women at varying risk of breast cancer

Cohort 2: BRCA1 or BRCA2 mutation carriers attending MRI & XRM for breast screening Genetic risk of breast cancer

BRCA1 and BRCA2 mutation carriers have a significant cumulative lifetime risk of developing breast cancer, estimated to be 65% and 45%, respectively by the age of 70 [42]. NICE guidelines recommend that these high risk women receive annual MRI screening from the age of 30, with the addition of annual XRM from the age of 40. At 50, continuation of MRI screening is dependent on breast density [43][44]. The Royal Marsden NHS Foundation Trust screened a large number of these women until 2013, when they were repatriated back into the NHS Breast Screening Service. At St George's Hospital NHS Trust, screening is currently taking place as a part of the NHS Breast Screening Service. Investigators will retrospectively analyse MRI and XRM examinations from women who were aged between 40 and 50 years at screening.

Cohort 3: Participants attending MRI & XRM for breast screening post mantle radiotherapy Environmental risk of breast cancer

Treatment with high dose mantle radiotherapy at a young age also confers a much higher risk of breast cancer than that of the general population, estimated to result in an increased relative risk of 14.4 in comparison with the general population. NICE guidelines recommend that these high risk women receive annual MRI screening from the age of 30, with the addition of annual XRM from the age of 40. At 50, continuation of MRI screening is dependent on breast density. The Royal Marsden NHS Foundation Trust screened a large number of these women until 2013, when they were repatriated back into the NHS Breast Screening Service. At St George's Hospital NHS Trust, screening is currently taking place as a part of the NHS Breast Screening Service. Investigators will retrospectively analyse MRI and XRM examinations from women who were aged between 40 and 50 years at screening.

Cohort 4: General population attending XRM for breast investigation Population risk of breast cancer

Symptomatic women within the general population are referred to the Rapid Diagnostic and Assessment Centre (RDAC) for breast investigations. A series of diagnostic tests are performed at the RDAC which can include XRM if the women are 40 years of age or above. MRI is not normally performed in this setting. Significant numbers of these women are found to have normal breast tissue at XRM. These are women who have a population (low) risk of breast cancer but who might potentially benefit from an MRI investigation. Investigators will prospectively invite these women for a clinical MRI breast screening examination.

The aim of this study is to develop quantitative MRI measurements of breast tissue from clinical MRI breast protocols and to demonstrate that these descriptors have potential value for breast cancer risk prediction.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date November 15, 2019
Est. primary completion date November 15, 2019
Accepts healthy volunteers
Gender Female
Age group 39 Years to 50 Years
Eligibility Inclusion Criteria:

Cohort 1:

- Normal breast tissue in one or both breasts

- Aged > 39.5 years

- = 6 months between XRM and MRI examinations

Cohort 2:

- Genetically proven BRCA1 or 2 mutation carrier

- Age 39.5 - 50.5 years

- = 6 months between XRM and MRI examinations

Cohort 3:

- Previous mantle radiotherapy

- Age 39.5 - 50.5 years

- = 6 months between XRM and MRI examinations

Cohort 4:

- Radiologically healthy breast tissue as assessed by XRM

- Age 39.5 - 50.5 years

- Able to attend MRI screening within 6 weeks of XRM

Exclusion Criteria:

Cohort 1:

- Treatment or medication between XRM and MRI examinations

Cohort 2:

- Previous breast cancer diagnosis and/or treatment

- Treatment or medication between XRM and MRI examinations

Cohort 3:

- Previous breast cancer diagnosis and/or treatment

- Treatment or medication between XRM and MRI examinations

Cohort 4:

- Previous breast cancer diagnosis and/or treatment

- MRI incompatible implants

- Claustrophobia

- Inability to tolerate a 40 minute MRI breast examination

- Patients with renal failure or problems with IV access

Study Design


Intervention

Diagnostic Test:
MRI
Clinical MRI breast screening examination

Locations

Country Name City State
United Kingdom The Royal Marsden NHS Foundation Trust Sutton Surrey

Sponsors (1)

Lead Sponsor Collaborator
Royal Marsden NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Arm 1 (Cohort 1), Arm 2 (Cohorts 2 & 3) : breast density Breast density is measured in standard clinical sequences and in research sequences, expected to be the gold standard, as a %volume. After retrospective selection of subject groups (approximately 6 months).
Primary Arm 1 (Cohort 1), Arm 2 (Cohorts 2-3) : breast parenchyma enhancement (BPE) BPE is measured as a % of pre-contrast image intensity on dynamic contrast-enhanced examinations. After retrospective selection of subject groups (approximately 6 months).
Primary Arm 2 (Cohort 4): breast density Breast density is measured in standard clinical sequences and in research sequences, expected to be the gold standard, as a %volume. Six months after recruitment
Primary Arm 2 (Cohort 4): breast parenchyma enhancement (BPE) BPE is measured as a % of pre-contrast image intensity on dynamic contrast-enhanced examinations. Six months after recruitment
See also
  Status Clinical Trial Phase
Recruiting NCT05036629 - Development of MRI Protocols and Associated Neuro-physiological Explorations in Healthy and Pathological Subjects N/A
Completed NCT02548819 - University Hospital Cardiac Device MR Registry: The Safety of MR Imaging in Patients With Implanted Cardiac Devices N/A
Completed NCT01168479 - FLAME: Investigate the Benefit of a Focal Lesion Ablative Microboost in Prostate Cancer Phase 3
Completed NCT00512226 - Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia N/A
Recruiting NCT05439330 - Application of a Dental-dedicated MRI in the Diagnosis of Temporomandibular Joint Disorders, Tissue Alterations Related to Third Molars, Periapical and Periodontal Inflammatory Diseases, and Implant Treatment Planning N/A
Not yet recruiting NCT05464576 - Tumor Staging T of Bladder Tumours: Correlation of MRI and Anatomopathologic Analysis N/A
Recruiting NCT04028375 - Study of CT and MR in the Gastric Cancer
Recruiting NCT04034667 - Study of CT and MR in the Lung Cancer
Recruiting NCT04231175 - Dedicated MR Imaging vs Surgical Staging of Peritoneal Carcinomatosis in Colorectal Cancer N/A
Completed NCT00949507 - Comparison of Two Regimens of Anesthesia for Children Undergoing Magnetic Resonance Imaging (MRI) in General Anesthesia Phase 4
Completed NCT01420211 - Influence of the OATP1B1 and OATP1B3 Genotype on the Hepatic Uptake of Primovist® Phase 1/Phase 2
Recruiting NCT05167669 - Pain Relief in Symptomatic Bone Metastases With Adjuvant Hyperthermia MR Guided HIFU Early Phase 1
Recruiting NCT05618990 - OPTIMIZATION of ADVANCED MR SEQUENCES
Recruiting NCT05107232 - OSV-IRM - Volunteer MRI Sequence Optimization N/A
Completed NCT00556101 - Patient Acceptance of Whole Body Magnetic Resonance Angiography N/A
Recruiting NCT03142698 - Evaluation of 4 MRI Methods (PDFF 3, 6 and 11 Gradient Echoes and Spectroscopy) Compared to the Reference Method (Liver Biopsy) in Quantification of Hepatic Steatosis N/A
Suspended NCT00554073 - Whole Body Magnetic Resonance Angiography in Ischemic Patients at 1.5 and 3T N/A
Completed NCT06366906 - 10-year Retrospective Study of Oral and Maxillofacial Squamous Cell Carcinoma
Not yet recruiting NCT05359497 - Value of MRCP+ And Liver Multiscan in the Management of Dominant Strictures in Primary Sclerosing Cholangitis N/A
Recruiting NCT05192629 - Intranasal Dexmedetomidine Versus Oral Midazolam as Premedication for Propofol Sedation in Pediatric Patients Undergoing Magnetic Resonance Imaging Phase 3